Preclinical to Human Scaling of Pharmacokinetics for Long-Acting Injectable Antiretrovirals
Background: Long-acting injectables (LAIs) have attracted interest for prevention and treatment of infection (including HIV, HCV and tuberculosis), addressing issues with pill burden and adherence. Better methods for scaling preclinical pharmacokinetics (PK) for prediction of human exposure are needed to aid decision making, and accelerate early clinical development through better human dose prediction. Methods: Matching…